BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38635931)

  • 21. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of T2285C polymorphism in PARP1 gene coding region with its expression, activity and NSCLC risk along with prognosis.
    Wang Y; Xia XB; Tang HZ; Cai JR; Shi XK; Ji HX; Yan XN; Xu T
    Mutagenesis; 2021 Aug; 36(4):281-293. PubMed ID: 34132814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
    Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
    Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.
    Jones MH; Virtanen C; Honjoh D; Miyoshi T; Satoh Y; Okumura S; Nakagawa K; Nomura H; Ishikawa Y
    Lancet; 2004 Mar; 363(9411):775-81. PubMed ID: 15016488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
    Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
    Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
    Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association of intravascular stromal cells with prognosis in high-grade neuroendocrine carcinoma of the lung.
    Sekihara K; Hishida T; Ikemura S; Saruwatari K; Morise M; Kuwata T; Fujii S; Kojima M; Ochiai A; Funai K; Aokage K; Yoshida J; Tsuboi M; Ishii G
    J Cancer Res Clin Oncol; 2016 May; 142(5):905-12. PubMed ID: 26696594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic implications of synaptophysin, CD56, thyroid transcription factor-1, and Ki-67 in pulmonary high-grade neuroendocrine carcinomas.
    He Y; Zhao L; Tang X; Jiang Q; Zhao X; Cao Y
    Ann Diagn Pathol; 2024 Feb; 68():152239. PubMed ID: 38006863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung.
    Ryuge S; Sato Y; Jiang SX; Wang G; Matsumoto T; Katono K; Inoue H; Iyoda A; Satoh Y; Yoshimura H; Masuda N
    Lung Cancer; 2012 Aug; 77(2):415-20. PubMed ID: 22572237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.
    Kotake M; Imai H; Kaira K; Endoh H; Yamada Y; Kaburagi T; Kiyoshima M; Sugiyama T; Nakamura Y; Kasai T; Matsuguma H; Minemura H; Kanazawa K; Suzuki H; Fujita A; Minato K
    Chemotherapy; 2022; 67(3):142-151. PubMed ID: 35313303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
    Wang H; Yan L; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Lin D
    Hum Pathol; 2023 Dec; 142():81-89. PubMed ID: 37742943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulinoma-associated protein 1 is a prognostic biomarker in pulmonary high-grade neuroendocrine carcinoma.
    Minami K; Jimbo N; Tanaka Y; Ogawa H; Hokka D; Nishio W; Yoshimura M; Itoh T; Maniwa Y
    J Surg Oncol; 2020 Aug; 122(2):243-253. PubMed ID: 32346887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung.
    Takahashi A; Ishii G; Kinoshita T; Yoshida T; Umemura S; Hishida T; Yoh K; Niho S; Goto K; Ohmatsu H; Ohe Y; Nagai K; Ochiai A
    J Cancer Res Clin Oncol; 2013 Nov; 139(11):1869-78. PubMed ID: 24013219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma.
    Li Z; Lv T; Liu Y; Huang X; Qiu Z; Li J
    Cancer Biomark; 2016 Mar; 16(4):633-9. PubMed ID: 27002766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnostic value of DNA repair gene in breast cancer metastasis.
    Yang Y; Li X; Hao L; Jiang D; Wu B; He T; Tang Y
    Sci Rep; 2020 Nov; 10(1):19626. PubMed ID: 33184404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    Gan A; Green AR; Nolan CC; Martin S; Deen S
    Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Base excision repair pathway: PARP1 genotypes as modulators of therapy response in cervical cancer patients.
    Nogueira A; Assis J; Faustino I; Pereira D; Catarino R; Medeiros R
    Biomarkers; 2017 Feb; 22(1):70-76. PubMed ID: 27323894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel 12-gene signature as independent prognostic model in stage IA and IB lung squamous cell carcinoma patients.
    Wang K; Li Y; Wang J; Chen R; Li J
    Clin Transl Oncol; 2021 Nov; 23(11):2368-2381. PubMed ID: 34028782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8
    Li Y; Shi X; Mao B; Wang L; Wu L; Li J; Jiao S
    Lung Cancer; 2022 Apr; 166():161-169. PubMed ID: 35287068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.